Buy Tirzepatide Peptide Kit (10 Vials) | High-Purity Dual GIP and GLP-1 Research Peptide

Tirzepatide is a long-acting synthetic peptide and dual incretin receptor agonist extensively investigated in metabolic and endocrine research. Through simultaneous activation of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, Tirzepatide has become one of the most extensively characterized compounds in modern incretin biology.

Available in 10-vial kits containing 5 mg per vial, this research-grade peptide undergoes rigorous analytical testing to ensure exceptional purity, identity, and batch-to-batch consistency.

Product Highlights

• 10 vacuum-sealed lyophilized vials per kit
• 5 mg per vial
• ≥99% HPLC purity verified
• Mass spectrometry identity confirmation
• White lyophilized powder
• Certificate of Analysis (COA) available
• Excellent batch-to-batch consistency
• Intended exclusively for laboratory research

What Is Tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide designed to activate both GIP and GLP-1 receptors. Its dual incretin mechanism distinguishes it from traditional GLP-1 receptor agonists and has generated considerable scientific interest in studies involving metabolic signaling and endocrine physiology.

Because of its prolonged biological activity and receptor selectivity, Tirzepatide has become one of the most widely investigated peptide compounds in obesity, diabetes, and cardiometabolic research.

Discovery and Development

Tirzepatide was developed by Eli Lilly and Company during efforts to create next-generation incretin therapies. Pharmaceutical formulations marketed under the brand names Mounjaro® and Zepbound® have contributed to growing scientific interest in dual incretin receptor biology.

Since its introduction, Tirzepatide has been extensively studied in both preclinical and clinical settings, leading to significant advances in the understanding of metabolic regulation and hormonal communication pathways.

Timeline

• 2018 – Early clinical investigations expand.
• 2022 – Mounjaro® receives FDA approval.
• 2023 – Zepbound® receives FDA approval.
• Present – Ongoing investigations continue to explore the biology of dual incretin signaling.

Structural Characteristics

Tirzepatide is composed of 39 amino acids and incorporates structural modifications that improve albumin binding and prolong biological activity. These characteristics contribute to its extended half-life and sustained receptor activation.

Mechanism of Action

Researchers investigate Tirzepatide for its effects on:

• GLP-1 receptor signaling
• GIP receptor pathways
• Glucose metabolism
• Energy homeostasis
• Appetite-associated mechanisms
• Gastrointestinal physiology
• Endocrine communication networks

Primary Areas of Research

Incretin Biology

Tirzepatide is widely utilized in studies involving dual receptor activation.

Metabolic Research

Researchers investigate interactions between incretin signaling pathways and energy metabolism.

Endocrine Function

Experimental models explore hormonal communication mechanisms associated with dual agonism.

Gastrointestinal Physiology

Scientists continue to study the role of incretin receptors in digestive system biology.

Cardiometabolic Research

Researchers investigate relationships between metabolic pathways and cardiovascular physiology.

Tirzepatide vs Semaglutide

Tirzepatide vs Retatrutide

Product Specifications

Quality Assurance

Every batch undergoes:

• HPLC purity analysis
• Mass spectrometry identity confirmation
• Batch traceability verification
• Quality control inspection
• Certificate of Analysis documentation

Storage Guidelines

For optimal stability:

• Store at 2–8°C.
• Protect from heat and moisture.
• Avoid repeated freeze-thaw cycles.
• Keep containers sealed until use.

Frequently Asked Questions

What is Tirzepatide?

Tirzepatide is a synthetic peptide that acts as a dual agonist of the GIP and GLP-1 receptors and is widely investigated in metabolic and endocrine research.

Who developed Tirzepatide?

Tirzepatide was developed by Eli Lilly and Company as a next-generation incretin therapy.

Is Tirzepatide a peptide?

Yes. Tirzepatide is a synthetic peptide composed of 39 amino acids.

What receptor does Tirzepatide target?

Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors.

What brands contain Tirzepatide?

Pharmaceutical formulations containing Tirzepatide are marketed under the brand names Mounjaro® and Zepbound®.

What are the most popular Tirzepatide products available in the United States?

Mounjaro® and Zepbound® are the most recognized Tirzepatide products available in the United States. Both formulations were developed by Eli Lilly and have contributed significantly to scientific interest in dual incretin receptor biology.

How does Tirzepatide compare to other GLP-1 receptor agonists for weight management?

Tirzepatide differs from conventional GLP-1 receptor agonists because it activates both GIP and GLP-1 receptors. This dual incretin mechanism has been extensively investigated in clinical studies involving body weight regulation and metabolic physiology. Compared with compounds such as Semaglutide and Liraglutide, Tirzepatide represents a distinct approach to incretin signaling and has generated considerable scientific interest in obesity and weight management research.

What is the typical out-of-pocket cost for Tirzepatide without insurance?

Retail pricing for branded Tirzepatide products without insurance can vary depending on pharmacy, dosage strength, and geographic location. In the United States, monthly costs for products such as Mounjaro® and Zepbound® are frequently reported to exceed $1,000 without insurance coverage. Pricing may change over time, and individuals should consult manufacturers or pharmacies for the most current information.

Is Tirzepatide used in weight loss research?

Yes. Tirzepatide has been extensively investigated in studies involving body weight regulation, energy homeostasis, appetite-associated pathways, and metabolic signaling. Its dual receptor activity has made it one of the most important compounds in modern obesity and cardiometabolic research.

What is the difference between Tirzepatide and Semaglutide?

Tirzepatide activates both GIP and GLP-1 receptors, whereas Semaglutide primarily targets the GLP-1 receptor.

Is a Certificate of Analysis available?

Yes. Certificates of Analysis are available to verify identity and purity.

Related Research Compounds

• Semaglutide
• Retatrutide
• Cagrilintide
• Liraglutide
• Tesofensine
• AOD-9604

Scientific References

• Coskun T, Sloop KW, Loghin C, et al.
• Frias JP, Davies MJ, Rosenstock J, et al.
• SURPASS Clinical Trial Program.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al.
• Peer-reviewed literature concerning GIP and GLP-1 receptor biology.

Conclusion

Tirzepatide represents a major advancement in incretin research. Through its dual GIP and GLP-1 receptor activity and extensive scientific characterization, it has become one of the most important compounds for studying metabolic physiology, obesity biology, endocrine signaling, and cardiometabolic regulation.

Research Use Only

Tirzepatide is supplied exclusively for laboratory research purposes. This product is not intended for human or veterinary use and is not approved to diagnose, treat, cure, or prevent any disease.

Scientific Resources

For more detailed scientific information, you can visit the PubChem entry for Tirzepatide.

Related Research Peptides

• AOD 9604: 2-5mg*10 vials
• Semaglutide: 2-5-10mg*10 vials